|Generic name||Ibritumomab tiuxetan|
|Brand name(s), other common name(s)||Zevalin®|
|Drug type||Monoclonal antibody, radioimmunotherapy|
|How the drug is given||Intravenously (IV)|
Ibritumomab tiuxetan is FDA approved to treat people who have relapsed or refractory, low-grade or follicular non-Hodgkin lymphoma (NHL), including patients with follicular NHL that did not respond to therapy with rituximab. It is also FDA approved to treat patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. This drug is a monoclonal antibody with an attached radioisotope to deliver radiation therapy to the lymphoma cells.
Side effects needing medical attention:Rash; fever; weakness; headache; dizziness; shortness of breath; coughing; unusual tiredness or fatigue; unusual bruising or bleeding; itching; flushing; muscle or joint pain; abdominal pain; nausea; vomiting; diarrhea.
Side effects needing medical attention after stopping this medication: Bleeding gums; blurred vision; bone pain; chills; confusion; cough; coughing up blood; difficulty in breathing or swallowing; rapid, shallow breathing or shortness of breath; dizziness; fainting; fast heartbeat; fever; headache (sudden and severe); inability to speak; increased menstrual flow or vaginal bleeding; lightheadedness; lower back or side pain; nosebleeds; painful or difficult urination; pale skin; paralysis; prolonged bleeding from cuts or unusual bleeding or bruising; red or dark brown urine; red or black, tarry stools; seizures; slurred speech; sore throat; temporary blindness; ulcers, sores or white spots in mouth; unusual tiredness or weakness; weakness in arm and/or leg on one side of body (sudden and severe).